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A central goal of cancer research is to discover and characterize the functional effects of mutated genes that contribute to
tumorigenesis. In this study, we provide a detailed structural classification and analysis of functional dynamics for members of
protein kinase families that are known to harbor cancer mutations. We also present a systematic computational analysis that
combines sequence and structure-based prediction models to characterize the effect of cancer mutations in protein kinases.
We focus on the differential effects of activating point mutations that increase protein kinase activity and kinase-inactivating
mutations that decrease activity. Mapping of cancer mutations onto the conformational mobility profiles of known crystal structures
demonstrated that activating mutations could reduce a steric barrier for the movement from the basal “low” activity state to the
“active” state. According to our analysis, the mechanism of activating mutations reflects a combined effect of partial destabilization
of the kinase in its inactive state and a concomitant stabilization of its active-like form, which is likely to drive tumorigenesis at
some level. Ultimately, the analysis of the evolutionary and structural features of the major cancer-causing mutational hotspot in
kinases can also aid in the correlation of kinase mutation effects with clinical outcomes.

1. Introduction
The human protein kinome presents one of the largest protein
families that orchestrate functional processes in complex
cellular networks during growth, development, and stress
response [1–5]. The allosteric regulation of protein kinases
serves as an efficient strategy for molecular communication
and event coupling in signal transduction networks. Protein
kinases are enzymes with a conserved catalytic domain
that phosphorylates protein substrates and thereby play a
critical role in cell signaling pathways [1–5]. Abnormal
activation or regulation of protein kinases are major causes
of human diseases, especially cancers. In fact, mutations in
protein kinases often exemplify the phenomenon of “oncogene addiction,” whereby the structural effects of a specific
set of mutations are necessary for a tumor to proliferate

and hence have a selective advantage for tumor formation
during somatic cell replication. As a result, protein kinases
are important therapeutic targets for combating diseases
caused by abnormal cell signaling [6–12]. Although the kinase
catalytic domain is highly conserved, protein kinase crystal
structures have revealed considerable structural differences
between the closely related active and highly specific inactive
forms of kinases [13–15]. The structures adopted by inactive
kinases generally differ dramatically in the vicinity of the
activation loop residues, in contrast to the well-conserved
structures seen in active kinases [16–31]. Protein kinases
interconvert between functionally important active and inactive states of the enzyme, and the phosphorylation of key
residues can shift the balance between these states [13–
15]. Evolutionary conservation and conformational plasticity
of the kinase catalytic domain allow kinases to effectively
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achieve a dynamic equilibrium between active and inactive
forms. This equilibrium ultimately facilitates regulation of
their catalytic activity and recognition by other molecules.
A steadily growing wealth of structural knowledge about
the kinase catalytic domain and kinase complexes with
inhibitors has demonstrated that protein kinase activity can
be tightly regulated via dynamic interconversion between
closely related active and highly specific inactive kinase
states—a structural hallmark of the kinase domain which is
critical for its normal function. What differentiates one kinase
from another is the diversity of input signals that impinge on
the catalytic domain, and a rich variation in the mechanisms
that convert inactive forms of the kinase to active ones. The
remarkable variability of kinase conformational states, which
can include active, inactive, intermediate, and inactive-like
conformations, has confirmed that diverse structures of the
kinase activation loop may reflect natural kinase conformations and the dynamic equilibrium that occurs between them
[27]. Thus, the interconversion between distinct inactive and
active kinase states is an important characteristic feature of
the kinase domain. Consequently, activating mutations that
may perturb this equilibrium can result in an imbalance that
can shift the kinase towards the active conformation and
thus have a dramatic effect on the regulation of the enzyme.
The Cancer Genome Atlas and related DNA sequencing initiative (http://www.cancergenome.nih.gov/) have motivated
sequencing studies of tumors, all of which have produced
initial results that suggest that the underlying genomic basis
of tumorigenesis is complex [32–43].
Mutations in protein kinases, which are often implicated
in many cancers, can exemplify the phenomenon of “oncogene addiction,” whereby the structural effects of a specific
set of mutations are necessary for a tumor to proliferate
and hence have a selective advantage for the formation of
the tumor during somatic cell replication. A recent sequencing study of kinase coding regions in tumors attempted
to differentiate which kinase gene mutations can cause
the cancer phenotype (known as “driver mutations”) and
which mutations are simply neutral mutational byproducts
of somatic cell replication (known as “passenger mutations”)
[38]. This study identified ∼200 putative driver mutations
among ∼100 out of 254 kinases in 139 tumors. Another recent
sequencing study described a systematic analysis of 13,023
well-annotated human protein-coding genes in 11 breast and
11 colorectal cancers in an initial “discovery” screen, followed
by an analysis of 24 additional breast or colorectal tumors
in a “validation” screen [39]. This study identified 189 genes
displaying somatic mutations. The emerging mutational
“landscape” of human cancers described in these papers
suggests that only a few specific mutations are observed
across different tumors (referred to as “mountains”) and
many mutations appear to be common in small subsets of
tumors [40]. The genomes of a malignant melanoma and
a lymphoblastoid cell line have been sequenced from the
same person, providing the first comprehensive catalogue of
somatic mutations [41]. Other studies have classified tumorassociated somatic mutations according to their involvement
in tumorigenesis by describing the mutational spectrum of
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18, 191 distinct genes in 11 breast and 11 colorectal tumors
through a systematic sequencing of exons.
Tumor sequencing efforts have identified a rich source
of naturally occurring mutations with many being simple
single nucleotide polymorphisms (SNPs) in kinases. A subset
of these SNPs occurs in the coding regions (cSNPs) of
kinases and results in a change in the encoded amino acid
sequence (nonsynonymous coding SNP; nscSNPs). It is not
clear, however, which of these nscSNPs actually contribute to
tumorigenesis as “drivers.” Recent evidence suggests that cancer drivers have characteristics similar to Mendelian disease
mutations [44]. Based on this information, a computational
tool for predicting cancer-associated missense mutations,
CanPredict, was developed [45]. Though quite powerful,
generalized prediction methods such as CanPredict may
fail to achieve the sensitivity and specificity attainable by
prediction models tailored to individual protein families.
We have also pursued a number of studies investigating the
utility of sequence-based structural and evolutionary analysis
of the effects of protein kinase nscSNPs using machine
learning models [46–48]. A comprehensive computational
analysis of the distribution of 1463 nscSNPs and 999 diseasecausing nscSNPs within the kinase gene family has shown
that disease-associated variations are overrepresented in the
kinase catalytic domain [46]. A support-vector machine
(SVM) analysis model was then developed to differentiate
disease-associated nsSNPs from neutral nsSNPs in protein
kinases [47]. By leveraging structural, phylogenetic, and
physiochemical attributes, this method predicted known cancer driver mutations in protein kinases contributing to cancer
progression. Using multiple subdomain based alignments, we
have predicted that conserved positions harboring cancerassociated somatic mutations (CASMs) in multiple protein
kinases contained a high proportion of predicted drivers,
while kinase subdomains devoid of CASMs were more
likely to contain passenger mutations [48]. In particular, we
have identified a number of structurally conserved positions
within the protein kinase catalytic core that appears to be frequent targets of tumorigenic mutations [48]. This suggests the
existence of mutational hotspots, that is, conserved positions
in the kinase catalytic domain, which may be statistically
enriched in cancer and disease-causing mutations. We have
also systematically catalogued disease and common SNPs,
that is, those not known to cause disease, residing within
the kinase catalytic core and then mapped them to individual subdomains, which are characterized by patterns of
conserved residues [49]. It appears that the catalytic domain
of protein kinases harbors a large number of disease causing
nsSNPs as well as common or neutral nsSNPs that are not
known to be associated with any diseases. We have found that
while neutral kinase nsSNPs are randomly distributed within
the catalytic core, known disease-causing nsSNPs are not
directly involved in ATP binding but rather map to regulatory
and substrate binding regions [49]. In contrast, cancer SNPs
tend to lie closer to the catalytic machinery of protein kinases.
As an example of the importance of the characterizing
the structural properties of genetic variations identified in
tumors, consider that, for nonsmall cell lung carcinoma, systematic resequencing of tyrosine kinase genes has identified
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somatic mutations within the epidermal growth factor receptor (EGFR) tyrosine kinase gene [50–52]. The spectrum of
lung cancer-derived EGFR mutations can induce oncogenic
transformation by leading to constitutive kinase activity of
EGFR and confer markedly different degrees of sensitivity
to EGFR inhibitors. The discovery of activating mutations in
the EGFR kinase domain and their differential sensitivity to
inhibitors has suggested a potential structural divergence of
the kinases in response to activating mutations and respective
differences in the inhibitor binding [53–55]. Structural determination of the EGFR wild-type kinase and cancer mutants
in complexes with inhibitors and interacting proteins has
recently produced molecular insights into the functional
effects of protein flexibility and relevant genetic modifications
of this flexibility [56–59]. Using mutational analysis and
crystallography it was discovered that the autoinhibited
conformation of the EGFR kinase domain can resemble that
of Src kinase and cyclin-dependent kinases [56, 57]. These
structural studies have provided evidence that the active
conformation previously observed in crystals of the EGFR
kinase domain may have been a consequence of mimicry by
the crystal (or by the inhibitor) of the intrinsic activation
mechanism that can shift the dynamic equilibrium away
from the otherwise stable inactive Src-like conformation. The
structures of the wild-type EGFR kinase and mutants in
complexes with a range of inhibitors have provided invaluable
insights into the role of activating mutations in the EGFR
kinase domain and their differential sensitivity to inhibitors
[59]. The identification of EGFR mutations in a subset of
human lung carcinomas and the association between EGFR
mutation and drug sensitivity have suggested that genetic
alterations in specific kinases and corresponding changes in
structural and interaction profiles of kinases render tumors
sensitive to selective inhibitors.
Some somatic mutations in kinases driving cancer may
inactivate the catalytic activity of a kinase. In kinome-wide
unbiased screens for kinase mutations in cancer, a large
number of such inactivating mutations have been uncovered
[60, 61]. The kinase-dead mutants of the catalytically important Asp residue from the DFG motif have been found in
various kinases including BRAF [62, 63] as well as DAPK3,
HCK, and LYN [60, 61]. The increasingly growing fraction
of cancer driver mutations emerging from sequencing studies of protein kinase genes appeared to be inactivating or
kinase dead leading to the loss of function. These studies
have revealed that constitutively activating and kinase-dead
mutations could play context-dependent opposing roles in
cancer and may be simultaneously present in a variety of
oncogenic kinases such as FGFR2/FGFR3 [64–68], MAP2 K4
[69], EPHA3 [70], DAPK3 [71], TRKB [72], ITK [73], and
LKB1 [74]. These kinase-inactivating mutations have been
found in various cancers and may represent a future class of
drug targets.
Structural and computational approaches have been
instrumental in revealing the atomic details of the protein
kinase dynamics at different levels of complexity: from the
detailed analyses of the catalytic domain to simulations of
the regulatory dimer assemblies [56, 75–77]. In a pioneering
computational study Shaw and colleagues have pushed the
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boundaries of simulation time scales to a new level revealing
that oncogenic mutations in the EGFR kinase may reduce
the disorder in the 𝛼C-helix region and in the dimerization
interface, thereby facilitating the formation of asymmetric
active EGFR dimer [75]. We have recently reported a series
of computational investigations of oncogenic protein kinases
that analyzed mechanisms of allosteric regulation in ABL
and EGFR kinases by integrating multiscale simulations and
modeling of long-range communications in the regulatory
complexes [78, 79]. The results have unveiled organizing
principles of mutation-induced activation in the ABL and
EGFR kinases that may be orchestrated by a cross-talk
between the integrating 𝛼F-helix and the mediating 𝛼C-helix,
responsible for coordination of the interdomain coupling
between key regulatory regions.
Despite significant advances in understanding structure
and function of oncogenic mutations in protein kinases, a
systematic analysis of structural and evolutionary characteristics of kinase-activating and kinase-inactivating cancer
mutations across a significant fraction of human kinome is
still lacking. In the current study, we employ a computational approach that combines sequence and structure-based
prediction models to classify and characterize the effect of
cancer mutations in protein kinases. We provide a detailed
structural classification and analysis of functional dynamics
for members of protein kinase families that are known to
harbor cancer mutations. In particular, we characterize global
features of functional dynamics for members of the EGFR,
CDK, NEK, BTK, and ITK kinases that have various cancer
mutations. Sequence and structure-based prediction models
are then combined with the analysis of functional dynamics and collective motions to classify and characterize the
effects of cancer mutations in protein kinases. Based on our
analyses, we identify and characterize evolutionary conserved
cancer-causing kinase mutational hotspots. We also focus
on differential effects of activating and inactivating point
mutations that allow modulating protein kinase activity. We
show that kinase-inactivating mutations are often located in
structurally rigid sites where mutations could either stabilize
the autoinhibitory inactive state and prevent activation or
severely reduce kinase activity through detrimental changes
in the kinase fold. Evolutionary and structurally derived
models of major cancer mutation hotspots are used to
develop mechanistic understanding of mutation-induced
regulation of kinase activity. The results of this study suggest
that an understanding of the evolutionary and structural
signatures of cancer-causing kinase mutations may provide
a roadmap for the design of drugs that target specific
mutational hotspots and thus facilitate an era of the precision
medicine.

2. Results
2.1. Structural Analysis and Classification of the Protein
Kinases with Cancer Mutants. The mechanisms that regulate
catalytic activities of protein kinases can be categorized into
phosphorylation, autoinhibition, and allosteric activation by
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Figure 1: Structural analysis of the Cdk/Src kinases. The crystal structure alignment of the Cdk/Src kinases is presented separately for 3 groups
of evolutionary related kinases. A diverse spectrum of the Cdk/Src kinases has a common structural determinant: the regulatory 𝛼C-helix
assumes a 𝛼C-out conformation and prohibits the formation of the catalytically competent form. (a) The inactive crystal structures of Abl
(pdb id 2G1T), Csk (pdb id 1BYG), Hck (pdb id 2HCK, 1AD5), Src (pdb id 2PTK, 1KSW, 1FMK), Btk (pdb id 3GEN, 3OCT), Itk (pdb id 3QGY,
1SM2), and BMX kinases (pdb id 3SXS). A close-up view of the 𝛼C-helix region in these structures (d). (b) The inactive structures of EGFR
(pdb 1XKK, 2GS7), Her2 (pdb id 3PP0, 3RCD), Her3 (pdb id 3LMG,3KEX), Her4 (pdb id 2R4B, 3BBT, 3BCE), Tyk2 (pdb id 3NYX), Tie2
(pdb 2OSC), Met (pdb 2G15), Ron (pdb 3PLS), and Mer kinases (pdb id 2P0C). A close-up view of the 𝛼C-helix region in these structures
(e). The remaining Cdk/Src crystal structures, representing distinct branches of the kinome tree, were assembled into one group. (c) The
inactive structures of Cdk4 (pdb id 3G33), Cdk7 (pdb id 1UA2), Nek2 (pdb id 2W5H), Nek7 (pdb id 2WQM), MPSK (pdb 3DBQ), IRE1 (pdb
id 2RIO), KSR2 (pdb id 2Y4I), ILK (pdb id 3KMU), WNK1 (pdb id 3FPQ), RSK1 (pdb id 2Z7S), OSR1 (pdb id 2VWI), MST4 (pdb id 3GGF),
and CAMK1D (pdb 2JC6). A close-up view of the 𝛼C-helix region in these structures (f). The protein kinase structures are colored according
to their secondary structure. The inactive position of the 𝛼C-helix-out is highlighted (colored in green). A close-up view highlights structural
rigidity of the 𝛼C-𝛽4 loop and certains variability of the 𝛼C-helix within the catalytically inactive position.

binding partners [80–83]. Protein kinases are commonly regulated by phosphorylation of their activation loops that initiates a cascade of conformational changes enabling the kinase
domain to adopt a catalytically competent conformation [82,
83]. For a number of kinases, however, phosphorylation may
not be sufficient to guarantee the acquisition of biological
activity. Some kinases may use more than one of these
mechanisms to trigger functional transitions between inactive and active states. Mechanisms that prevent the untimely
activation of kinases are crucial to ensure the proper cell
division. Autoinhibition is one of these mechanisms in which

kinases can adopt in the apo form an autoinhibited ordered
conformation that prevents inappropriate kinase activity.
Many protein kinases are regulated by structural mechanisms
of autoinhibition, including EGFR, BRAF, CDKs, families of
BTK, and NEK kinases. Structural coupling of the catalytic
DFG motif and the regulatory 𝛼C-helix is recognized as
central in controlling kinase activity and equilibrium between
the inactive (DFG-out/𝛼C-helix-in), the Cdk/Src-like inactive (DFG-in/𝛼C-helix-out), and the active kinase forms
(DFG-in/𝛼C-helix-in) [83, 84]. The basic functional modes
of autoinhibition are the binding of a regulatory domain to

Computational and Mathematical Methods in Medicine
the catalytic domain and a conformation of the activation
segment that blocks the nucleotide binding site. The defining
feature of an autoinhibited conformation in protein kinases
is that it can be reversed by activating mutation, leading to
dramatic increases in kinase activity. Among protein kinases
that fall into this category are most of the kinases harboring
disease-causing mutations (both activating and inactivating).
A common regulatory theme for one class of protein
kinases with cancer mutations is based on sharing an
intrinsically stable Cdk/Src structure and exhibiting a low
catalytic activity of their isolated catalytic domains (Figure 1).
Allosteric regulation of the Cdk/Src kinases occurs through
targeted engagement of external binding partners that can
perturb and destabilize the Cdk/Src inactive conformation,
thus promoting activation [85, 86]. The Cdk/Src inactive
structures are broadly distributed on the human kinome
tree, covering all kinome groups, most notably TK, TKL,
STE, CAMK, and CMGC families (Figure 1). The dominant
cluster of the Cdk/Src kinases is located in the TK and TKL
kinome groups and corresponds to the protein kinases with
the Cdk/Src inactive conformation. A significant portion of
the Cdk/Src-like kinases belongs also to the CMGC and STE
protein kinase groups. A diverse spectrum of the Cdk/Srclike inactive structures is unified by a common structural
determinant whereby the regulatory 𝛼C-helix is displaced
outwards the N-terminal lobe and assumes an 𝛼C-out
(swung-out) conformation, thus disallowing the formation
of the catalytic salt bridge and preventing the formation of
the catalytically competent form (Figure 1). Despite subtle
differences in regulatory mechanisms, a high degree of
structural conservation could be seen in the Cdk/Src inactive
states for Abl, Csk, Hck, Src, Btk, Itk, and BMX kinases
(Figures 1(a) and 1(d)). A greater conformational diversity
was observed in another subgroup of the Cdk/Src structures, represented by members of the EGFR/ErbB tyrosine
kinase subfamily (EGFR/Her1, ErbB2/Her2, ErbB3/Her3, and
ErbB4/Her4 kinases), members of the HGFR tyrosine kinase
subfamily (Met, Ron), and a member of the AXL tyrosine
kinase subfamily (Mer) (Figures 1(b) and 1(e)). The remaining
Cdk/Src crystal structures, representing distinct branches of
the kinome tree, were assembled into one subgroup (Figures
1(c) and 1(f)). Structurally conserved features of the Cdk/Src
kinases that determine their regulatory mechanisms are
exemplified by structural rigidity of the 𝛼C-𝛽4 loop that is
linked to the positional variability of the 𝛼C-helix within the
catalytically inactive state. The autoinhibitory interactions in
the Cdk/Src structures typically involve the activation loop
and the 𝛼C-helix that blocks the formation of the Lys-Glu
catalytic salt bridge and prevent access to the active enzyme
form. The critical features underlying kinase activation and
stabilization of an active structural form include a dynamic
assembly of the hydrophobic spine and consolidation of the
Lys-Glu catalytic bridge [87, 88].
2.2. Functional Dynamics Maps of Protein Kinases Families
with Cancer Mutations. In this section, we describe a comparative analysis of conformational dynamics performed for
a significant number of protein kinases with known cancer
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mutations. We establish connections between global motions,
regulatory activation mechanisms, and functional requirements to harbor cancer mutations. The principal collective
motions of protein kinases and kinase mutant structures were
analyzed using molecular dynamics (MD) simulations and
principal component analysis (PCA) of MD trajectories. The
structural distribution of the protein mobility and the crosscorrelation maps of protein residue fluctuations were computed along the dominant principal component modes. This
analysis identified the shapes of the low frequency modes and
the protein regions subjected to correlated and/or anticorrelated motions along the selected low frequency modes. A
typical conformational mobility map of a Cdk/Src-like kinase
along low frequency modes is characterized by a network of
connected structurally stable elements mainly determined by
the interactions between the 𝛼E-helix of the C-terminal lobe
and the 𝛼C-𝛽4-loop motif of the N-terminal lobe (Figures 2–
4). Structural analysis of the protein kinases with a Cdk/Srclike conformation shows a commonly displaced 𝛼C-helix
that can maintain a certain positional variation within the
“swung-out” form. A structurally rigid 𝛼C-𝛽4-loop linked to
a relatively mobile 𝛼C-helix presents a “dynamic signature”
of the Cdk/Src-like kinases that is likely to play role in
regulating functional transitions between inactive “𝛼C-out”
and active “𝛼C-in” positions. The boundary between the
𝛼E-helix/𝛼C-𝛽4-loop region and the 𝛼C-helix can define a
functional hinge connecting structurally rigid and flexible
regions of the N-terminal lobe that would guide coordinated
collective motions of the kinase catalytic domain. Structurally
rigid and conformationally flexible residues may often occupy
proximal positions to the hinge sites in allosteric protein
systems, where the residues located at the “border” between
regions of high and low structural stabilities could form
recognition sites and control global protein movements.
Based on this evidence, a functional region at the junction of
the 𝛼C-helix and the adjacent 𝛼C-𝛽4-loop may be responsible
for principal motions of the Cdk/Src-like kinases during
activation mechanisms.
2.3. Conformational Dynamics Profiles of EGFR Kinases.
Functional motions of the Cdk/Src-like kinases have displayed commonalities and subtle differences in the dynamics
of the 𝛼C-𝛽4 and 𝛼C-helix motifs that are unified by
a common functional goal destabilization of the Cdk/Src
inactive state and stabilization of the active state through
interactions with binding partners or activating mutations.
Kinase activation through an asymmetric head-to-tail dimerization of catalytic domains is a common regulatory scenario
of the EGFR/ErbB subfamily of tyrosine kinases [89–95].
The autoinhibitory intramolecular clamp formed between
the 𝛼C-helix and a short 𝛼-helix of the activation loop is a
conserved feature of the Cdk/Src inactive structure shared
by all EGFR kinases (Figure 2). Functional dynamics of the
inactive Her3 [96, 97] and Her4 kinases [98, 99] highlighted
the intrinsic structural stability of the autoinhibitory enzyme
form (Figure 2). Despite a shortened 𝛼C-helix in the crystal
structures of the Her3 receptor [96, 97], the broadened
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Figure 2: Functional dynamics and protein mobility maps of the EGFR subfamily of kinases. Conformational mobility maps of the Egfr/ErbB
tyrosine kinase subfamily (EGFR/Her1, ErbB2/Her2, ErbB3/Her3, and ErbB4/Her4 kinases) were computed using MD simulations of the
inactive crystal structures. Structural distribution of the protein kinase mobility is averaged over the two lowest frequency modes. A surfacebased protein representation is employed, colored (blue-to-red) according to the protein residue motilities (from more rigid-blue regions to
more flexible-red regions). A close-up of the regulatory hinge site formed by the 𝛼E-helix, 𝛼C-𝛽4 loop, and the 𝛼C-helix is shown on the right
panel. Structurally rigid 𝛼E-helix and 𝛼C-𝛽4 loop are linked at the hinge site to a more flexible 𝛼C-helix. The autoinhibitory intramolecular
clamp formed between the 𝛼C-helix and a short 𝛼-helix of the activation loop is a conserved feature of the EGFR kinases.

“rigid-blue” area of the catalytic core around the 𝛼C-𝛽4/𝛼Chelix region could lock the receptor in a stable Cdk/Srclike inactive form (Figure 2). The obtained dynamic profile
of the Her3 kinase corroborates with structural analyses by
Kuriyan’s [96] and Lennon’s groups [97] who attributed the
lack of Her3 catalytic activity to an overly stable inactive form.
Somewhat of a “family outlier” is the Her2 kinase [100], a
kinase with the increased conformational flexibility of the
inactive structure that is spread beyond the 𝛼C-helix region.
2.4. Conformational Flexibility Profiles of CDK and NEK
Kinases. The protein kinases harboring cancer mutations are
often regulated by similar activation mechanisms and are
involved in a similar cellular function. Mitotic phosphorylation events in the cell can be catalyzed by members of the
Cdk [101, 102] and Nek families [103–105] that are activated by

structurally similar mechanisms (Figure 3). The Cdk kinases
(Cdk2, Cdk4, and Cdk7) live by default in their stable
inactive Cdk/Src states and are activated through a cascade
of signaling events that include binding to their respective
cyclin partners: Cdk2-cyclin A [85, 86] and Cdk4-cyclin
D1 [101, 102]. While cyclin binding is sufficient to trigger
activation of Cdk2, the crystal structure of Cdk4 bound to
cyclin D1 revealed an inactive kinase conformation (Figure 3)
that remains thermodynamically stable even in the presence
of the binding partner. Structural studies suggested that
the Cdk4-cyclinD1 complex could present an intermediate
state in which Cdk4 is potentiated for final activation [101].
Functional dynamics of Cdk4 and Cdk7 kinases showed
subtle but important differences between these closely related
kinases, particularly revealing a greater rigidity of the inactive
Cdk4 state that is spread through the entire structural core
and the 𝛼C-𝛽4/𝛼C-helix region (Figure 3).
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Figure 3: Functional dynamics and protein mobility maps of the Cdk and Nek subfamilies of kinases. Conformational mobility maps of
the of the Cdk (Cdk4, Cdk7) (a, b, c) and Nek subfamilies (Nek2, Nek7) of kinases (d, e, f) were computed using MD simulations of the
inactive crystal structures. Structural distribution of the protein kinase mobility is averaged over the two lowest frequency modes. A surfacebased protein representation is employed and colored (blue-to-red) according to the protein residue motilities (from more rigid-blue regions
to more flexible-red regions). A close-up of the regulatory hinge site formed by the 𝛼E-helix, 𝛼C-𝛽4 loop, and the 𝛼C-helix is shown. The
characteristic autoinhibitory interactions are formed between a small helical motif within the activation loop and the 𝛼C-helix that prevents
access to the active enzyme form. The conserved functional residues (Tyr-70 in Nek2 and Tyr-97 in Nek7 shown in sticks on (f)) are projected
from the 𝛽4 strand of the N-terminal right down into the hinge site between the 𝛼C-𝛽4-loop and the 𝛼C-helix. These residues are implicated
in regulatory interactions of Nek kinases with binding partners.

Nek2, Nek7, and Nek9 are members of the human
Nek family [103–105] that are involved in mitotic function.
Activation of Nek kinases combines phosphorylation and
dimerization-dependent allosteric regulation by engaging
members of its own family as binding partners [106]. The
crystal structures of human Nek2 [106, 107] and Nek7 [108]
revealed a Cdk/Src-like inactive structure with characteristic
autoinhibitory interactions between a small helical motif
within the activation loop and the 𝛼C-helix that blocks the
formation of the Lys-Glu catalytic bridge and prevents access
to the active enzyme form (Figure 3). This autoinhibitory
clamp represents a common structural solution to a stable
inactive state that is also shared by Cdk and EGFR families
of kinases. Structural studies demonstrated that Nek7 can
be activated by engaging the noncatalytic domain of Nek9
in targeting and remodeling the vicinity of the 𝛼C-𝛽4loop [108]. Consistent with these experimental insights, we
find that functional dynamics of the 𝛼C-𝛽4 region and
the activation loop are similar in Cdks and Neks, where a
structurally rigid 𝛼C-𝛽4-loop is coupled to dynamic motions
of a more flexible 𝛼C-helix and the autoinhibitory helix of the

activation loop (Figure 3). Interestingly, the intramolecular
clamp in Cdk kinases is structurally more rigid as compared
to Neks (refer to a larger “blue” area near the autoinhibitory
helix in Figure 3). On other hand, the autoinhibitory small
helix in Nek kinases is less stable (Figure 3) and together with
the 𝛼C-helix forms a flexible component of the regulatory
hinge that is prone to functional changes. Hence, regulatory
interactions of Nek kinases with binding partners may be
readily facilitated by the coupled dynamics of the 𝛼C-𝛽4
and 𝛼C-helix motifs. This model is supported by structural
studies of Neks that pointed to a critical activation-promoting
role of the conserved tyrosine (Tyr-70 in Nek2 and Tyr-97 in
Nek7) that is projected from the 𝛽4-strand of the N-terminal
right down into the “border” area between the 𝛼C-𝛽4-loop
the 𝛼C-helix (Figure 3).
2.5. Conformational Mobility Maps of TEC Kinase Family.
The Tec family is a subfamily of nonreceptor type tyrosine
kinases and includes Btk, Itk, and Bmx kinases [109]. These
kinases share a common SH3-SH2-kinase organization also
found in the Src, Hck, Csk, and Abl kinases [110], yet they are
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Figure 4: Functional dynamics and protein mobility maps of the Tec subfamily of kinases. Functional dynamics and conformational mobility
maps of the Tec kinase subfamily (Btk, Itk, and Bmx kinases) were computed by using PCA of MD simulations of the inactive crystal
structures. Structural distribution of the protein kinase mobility is averaged over the two lowest frequency modes obtained from all-atom
MD simulations. A surface-based protein representation is employed and colored (blue-to-red) according to the protein residue motilities
(from more rigid-blue regions to more flexible-red regions). Two different close-up views of the regulatory hinge site formed by the 𝛼E-helix,
𝛼C-𝛽4 loop, and the 𝛼C-helix are shown on (a), (b), (c), (d), (e), and (f). The autoinhibitory electrostatic interactions between a helical motif
within the activation loop (Btk-R544 is shown in sticks) and the 𝛼C-helix (Btk-E445 is shown in sticks) are shown on (f). The conserved
Btk-M450 and Itk-M410 located near the regulatory hinge site (shown in sticks on the right lower panel) are critical activating residues.

regulated in an opposite manner. The disengagement of the
SH2-SH3 domains relieves the autoinhibitory constraints in
c-Src and Hck kinases and yields an activated form [110]. In
contrast, the catalytic domains of Btk, Itk, and Bmx kinases
adopt the Cdk/Src-like inactive structure and require binding
to the SH2-SH3 assembly for activation. The crystal structures
of the Btk, Itk, and Bmx catalytic domains in complexes with
inhibitors indicated that these kinases can be stabilized in
a number of distinct protein conformations that represent
variations of the catalytically inactive Cdk/Src-like structure
(Figure 4) [111–116]. The autoinhibitory electrostatic interactions between a helical motif within the activation loop
(Btk-R544) and the 𝛼C-helix (Btk-E445) protect the stability
of the inactive state (Figure 4). Functional dynamics of the
Tec kinases in their Cdk/Src-like inactive state displayed
a common protein mobility profile. It is worth noticing,
however, a uniform structural rigidity of the 𝛼E-helix and

the 𝛼C-𝛽4 loop in all Tec kinases. This contrasted with a
fairly mobile 𝛼C-helix as evident from our dynamic analysis
and reflected in the positional variability seen in the crystal
structures (Figure 4).
2.6. Structural and Functional Signatures of Cancer Mutations
in Protein Kinases. The catalytic domain of protein kinases
harbors a large number of SNPs falling into three major
categories: common and likely neutral SNPs, inherited disease causing (i.e., germline) SNPs, and cancer causing (i.e.,
somatic) SNPs. By compiling and mapping a total of 355
common SNPs, 428 inherited disease causing SNPs, and 541
cancer associated SNPs to the catalytic core of protein kinases
[117, 118], we find an enrichment of different categories
of SNPs in the different structural regions of the catalytic
domain (Figure 5). The widely varying distributions among
the three mutation types suggest that the different SNP types
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Figure 5: Structural distribution of protein kinase SNPs. The structural distribution of common SNPs (a), congenital disease-causing SNPs
(b), and cancer-associated SNPs (c) is depicted along with the frequencies of SNPs within specific structural domains (d). In (a)–(c), green
coloration represents regions with an SNP frequency equivalent to what would be expected by random chance, blue coloration represents
regions statistically devoid of SNPS, and red coloration depicts regions statistically enriched in SNPs. Note that regions enriched and devoid
of SNPs are different across the three mutation types, with minimal overlap. In (d) blue bars represent common SNPs, red bars represent
disease causing SNPs, and black bars represent cancer associated SNPs.

result in different types of functional consequences. Common SNPs sparsely populate important functional segments
such as the catalytic and activation loops, while densely
populate the C-terminal tail. Importantly, common SNP
hotspots occur at evolutionarily unconserved positions of
the C-terminal region. In contrast, inherited disease-causing
SNPs populate regions which are involved in regulation
and substrate binding, such as the APE-loop and the P+1
binding pocket, as well as the catalytic loop (Figure 5). In
turn, cancer associated SNPs strongly target catalytic and
nucleotide binding functions localizing to the P-loop, as
well as activation and catalytic segments of the catalytic
core. Though the regions enriched in cancer SNPs contain
highly conserved residues, cancer SNPs reveal a relatively
modest conservation pattern relative to disease SNPs and a
more diffuse distribution across the catalytic core (Figure 5).
There are overlaps in structural distribution for the three
SNP types, but the statistically enriched regions are nearly
completely distinct, presumably confirming the differences in
the functional effects of these three mutational types.
The contribution of sequence conservation to the evolutionary signature of cancer mutations and the overall

functional differences across all three SNP types is also
mirrored in the number of SNPs occurring at structurally equivalent positions across the protein kinase family
(Figure 6). Common SNPs, which are assumed to have
little functional affect, are randomly distributed throughout
the catalytic core. Therefore, the structural distribution of
common SNPs is dominated by positions mutated in a single,
or very few protein kinases. On the other hand, of the three
types of SNPs, inherited disease-causing SNPs tend to be
more highly concentrated at structurally equivalent positions,
with a significant excess of mutations occurring at positions
mutated in four or more different protein kinases (Figure 6).
This can be explained by the preference of inherited disease
SNPs for residues involved in substrate binding, allosteric,
or regulatory functions, where kinase activity is retained,
as is viability, but producing a biological deficit. Given that
somatic SNPs occur randomly and uniquely in each given
tumor, followed by selection for tumor cells with a growth
advantage, the position-specific distribution of cancer SNPs
is similar to common SNPs but is shifted towards a higher
number of SNPs per position, probably due to the selection
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Figure 6: The position-specific distribution of SNPs. The number of
common (blue), disease (red), and cancer (black) SNPs per position
is plotted against the frequency of SNPs occurring at structurally
identical positions. Note that the position-specific distribution of
cancer SNPs appears to be a hybrid of common and disease SNPs.

of tumorigenic mutational hotspots which are shared across
multiple protein kinases.
Somatic mutations occurring at structurally conserved
positions within the protein kinase domain tend to be
statistically enriched in tumors and cluster into specific
mutational hotspots. These cancer mutation hotspots occur
in functionally important protein kinase segments (Figure 7),
containing an abundance of predicted cancer driver mutations. Segments involved directly in catalytic functions, such
as the P-loop, catalytic loop, and activation loop tend to
be populated by cancer-causing mutations. On the other
hand, the C-helix, which undergoes large movements when
transitioning from the active to inactive conformation, is
significantly devoid of cancer mutations. The hinge region is
an intermediate case, where the segment does not appear to
contain an excess of cancer mutations. Evolutionary analysis
has identified that cancer mutation hotspots can cluster in
structurally conserved positions corresponding to L858, L718,
G721, T790, G796, D855, G857, and L861 in EGFR (Table 1),
which are localized within the P-loop, hinge region, and
activation loop (Figure 7).
We specifically focus on cancer mutation hotspots which
have been identified as a frequent target of tumorigenic
activating and inactivating mutations. A detailed structural
and conformational dynamics analysis was conducted for
major mutational hotspots of kinase-activating and kinasedead mutations, namely, (a) conserved hotspots corresponding to activating cancer mutants L858R and L861Q in EGFR
and (b) a conserved hotspot corresponding to the catalytic
Asp residue from the DFG motif implicated in kinase-dead
mutations in BRAF, DAPK3, HCK, and LYN (Table 1).
Based on these findings, we embarked on a detailed
comparative analysis of activating and inactivating mutations
on structure and dynamics of various kinase genes including
EGFR, BRAF, FGFR2, FGFR3, MAP2K4, EPHA3, DAPK3,
and TRKB kinases (Table 2) and we propose that structural
and dynamic signatures of cancer mutations may provide

and
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Figure 7: Structural mapping of cancer mutational hotspots in
protein kinases. The mutational hotspots are displayed using the
EGFR kinase (pdb entry 1M14). The C-helix devoid of cancer
mutations and drivers is shown in blue. The green hinge region
contains an excess of predicted driver mutations, and the red
catalytic and activation loops contain an excess of both cancer
mutations and predicted drivers. Green balls denote residues with
4 predicted driver mutations, yellow balls denote residues with 5
predicted driver mutations, and the red ball denotes L861, which is
predicted to be a driver in eight different kinases.

a clue to the underlying mechanism of kinase activation.
We test one of our hypotheses that the mechanism of
activating mutations may result from a combined effect of
the partial destabilization of the kinase in its inactive state
and a concomitant stabilization of its active-like form. We
also suggest that activating and inactivating mutations may
differentially target the catalytic domain based on structural
stability and flexibility of the kinase residues.
2.7. Structural Analysis and Conformational Dynamics of
the EGFR Cancer Mutants. Here we report the results of
structural modeling and dynamics analysis of the activating
cancer mutations in EGFR L858R and L861Q (Tables 1 and
2). An activating mutation in the activation loop of the
EGFR kinase domain, L858R (also identified as Leu834 in a
different numbering of the EGFR sequence), is among most
frequent mutations in lung cancer, amounting to more than
40% of EGFR mutations in this cancer category, and can
result in a dramatic enhancement of EGFR activity [50–52].
The crystal structures of EGFR-L858R and EGFR-T790M
[59] have shown that these cancer-causing modifications
could stabilize the active kinase form. We pursued structural
modeling of L858R mutant starting from both inactive (pdb
entries 1XKK, 2GS7) and active wild-type EGFR structures
(pdb entries 2J6M, 2ITX, 2ITW, and 2ITY). The predicted
structural models and dynamics analysis of the L858R EGFR
mutant conforms rather closely to the mutant X-ray structure
(pdb entry 2ITT), moving considerably away from the initial
wild type crystal structures and accurately reproducing the
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Table 1: Structurally conserved cancer mutation hotspots in protein kinase genes.
Reference (EGFR)

Segment

Number of mutations

Number of drivers

L718

P-loop

4

4

G721

P-loop

5

4

T790

Hinge

6

5

G796

Hinge

5

5

D855

Activation

5

5

G857

Activation

6

5

L858

Activation

3

3

L861

Activation

8

8

conformational rearrangement of the activation loop towards
the active-like state (Figure 8) [59].
In agreement with structural experiments [27], we found
that EGFR-L858R may be incompatible with the immediate
hydrophobic environment in the inactive structure which
disfavors a polar side chain of EGFR-L858R. The mobility
profiling of the inactive wild-type EGFR (Figure 8(a)) showed

Mutations
ABL L248V
BRAF I462S
EGFR L718P
JAK3 L527P
EGFRG721
BRAF G464A/E/R/V
caMLCK G601E
MLK2 G107E
NDR2 G99A
AurC G52E
EGFR T790M
ABL T315I/N
FGFR4 V550M
KIT T670E
PDGFRa T674I
NEK11 T108M
EGFR G796S
ABL G321E
ErbB2 G804S
IRR G1065E
LKB1 G135R
BRAF D594E
DAPK3 D161N
HCK D378G
LKB1 D194V
LYN D385Y
BRAF G596R
EPHA3 G766E
FYN G410R
JNK1 G171S
MAST2 G655A
CDK11 G175S
EGFR L858R
BRAF L596V
ErbB2 L866R
EGFR L861Q/R
ABL L387M
BRAFV600D/E/G/K/L/M
ErbB2 L869Q
FLT3 D835E/F/H/N/V/Y
KIT D816E/F/V/H/I/N/V
MET D1246H/N/V
PDGFRa D842I/V/Y

Activation status
Activating

Activating

Activating

Activating

Inactivating

Inactivating

Activating

Activating

that L858 and L861 are located in the regions that are
only marginally stable and therefore the introduction of the
energetically unfavorable side chains would destabilize the
inactive form and facilitate a transition to the active kinase
form. In the crystal structure of the wild-type EGFR in the
active state, Leu858 and L861 are surface exposed, with the
backbone carbonyl oxygen of Leu858 making hydrogen bond
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Table 2: Summary of modeled somatic kinase mutations.

Kinase

Mutations
L248V, T315I/L/N
G321E, Y353H, L387M
L718/P
G719C/A/R/D/V/S
G721D
L747S/P/F
V765M, V769L, T790M
G796S, L833V, T854A
D855
L858R, L861Q/R
G466E/V, D594E/V, G596R
L597V/S/Q/R/L
A598V, T599I/A, V600E/K/R/M
I548V, N550K, E565G, E565A
N549H, N540K, K526E,
K660E, R678G, K641R, G663E

Activation status
Activating
Activating
Activating
Activating
Activating
Activating
Activating
Activating
Inactivating
Activating
Inactivating
Activating
Activating
Activating
Activating
Activating

E636K, M640I, I642V, R759Q, E475K
D530N, A648T, G701S
I538V, N540K, K650E

Inactivating
Inactivating
Activating

K508
P712T, H713R, S772N, D127H
K503M
Q142L, R134Q
R154W, P326L, S251N, N234I
T112M, D161N, P216S
D378G
D385G
D194V
G410R
R728L, K761N, D678E, G766E, D806N
G171S
G175S
G655A
T695I, D751N
I767M, D769H/Y, V773AV777L,

Inactivating
Activating
Inactivating
Activating
Inactivating
Inactivating
Inactivating
Inactivating
Inactivating
Inactivating
Inactivating
Inactivating
Inactivating
Inactivating
Inactivating
Activating

ERBB2

T798M, G804S, Y835F, V842I,
T862A, L866R, L869Q, R896C

Activating
Activating

ERBB3

K753M
V714M, Q809R, V855A, S846I, E298C
V696I, A748S, E785K, R757Q, P829Q, T901M

Inactivating
Activating
No effect on kinase activity

K726R, D818N, D836Q

Inactivating

ABL

EGFR

BRAF

FGFR2

FGFR3
FGFR4
MAP2K4
DAPK3
HCK
LYN
LKB1
FYN
EPHA3
MAPK8
CDK11
MAST205
TRKB

ERBB4

interactions with Arg836 and the ion pair between Lys745
and Glu762 intact in this conformation (Figure 8(b)). The
effect of the L858R mutation results in destabilization of the
inactive conformation and stabilization of the active state
by enhancing rigidity of the 𝛼C-helix regulatory segment.
An inspection of the predicted structural model indicated
that important interactions formed in the crystal structure

of EGFR-L858R could be adequately reproduced, including a
stable K745-E762 ion pair, known as a critical attribute of the
active kinase form. The key interactions which stabilize the
L858R mutant in the active state are made by the side chain
of Arg858, which becomes ordered and forms a hydrogen
bond with the main chain carbonyl of Arg836 as well as the
hydrogen bond between Lys745 and Glu762 (Figure 9). In the
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Figure 8: Structural modeling and dynamics profile of L858R EGFR mutant. (a) The dynamics profile of the inactive wild-type EGFR (pdb
id 1XKK). (b) The dynamics profile of the active wild-type EGFR (pdb id 2J6M) crystal structure of the wild-type EGFR. (c) The structural
model and dynamics profile of the L858R mutant. The L858, L858R, and L861 residues are shown in sticks and colored according to their
mobility profile. The hydrophobic regulatory spine residues (M766-L777-H835-F856-D896) are shown in spheres. Structural distribution
of the protein kinase mobility is averaged over the two lowest frequency modes obtained from all-atom MD simulations. A surface-based
protein representation is employed, colored (blue-to-red) according to the protein residue motilities (from more rigid-blue regions to more
flexible-red regions).

L858R mutant model, Arg858 forms an extensive hydrogen
bond network which includes interactions with Asp837 (catalytic loop), Glu762 (𝛼C-helix), and Asp855 (activation loop)
(Figure 9). Hence, we observed that, in the EGFR-L858R
mutant, the substitution of the hydrophobic Leu in the activation loop with a charged residue results in the stabilizing
interactions with the residues from the 𝛼C helix (Figure 8(c)).
The structural mobility map of the L858R mutant revealed the
increased rigidity (marked by propagation of the blue color)
that is spread beyond the mutational site and resulted in
stabilization of the activation loop as well as the interactions
between L858R and the 𝛼C-helix. It could be also seen
that the 𝛼C-helix conformation becomes more stable in the
active form (Figure 8(c)). The L858R mutation was originally
proposed to function by destabilizing the inactive conformation of the activation loop, thus inducing thermodynamic
stabilization of the constitutively active conformation [56,
59]. In the most recent long-time scale simulation, an indirect
activation mechanism was suggested according to which
L858R transformation could suppress the disorder in the 𝛼Chelix region, thus favoring dimerization and formation of the
active dimer [75]. Here, we presented the large scale dynamics
analysis of the kinase catalytic domain for many kinases
and cancer mutants. Although our analysis of EGFR-L858R
is based on simulations of the catalytic domain, we found
that stabilizing effects favoring the formation of the active
catalytic domain conformation and asymmetric dimerization
stabilizing the interfacial 𝛼C-helix region are synergistic and
cooperative in nature reactions that act collectively to produce the phenotypic response. In other words, the observed
formation of the active kinase conformation, accompanied
by partial reduction of flexibility in the 𝛼C-helix, presents
a necessary prerequisite for asymmetric dimerization and
formation of the active dimer seen in [75]. To summarize, our
results are consistent with these studies and offer additional

important insights concerning synergistic nature of different
stages involved in the activation mechanism. The global effect
of these steps is to shift the balance toward the active state
and favor the formation of the asymmetric dimer. Structural
modeling of the EGFR-L861Q mutant has also unveiled a
considerable conformational rearrangement change, which
is largely localized in the activation loop, while the global
changes are rather moderate. We detected that a salt bridge
interaction between Lys745 (P-loop) and Glu762 (𝛼C-helix),
present in the wild-type structure, is also maintained in the
mutant model. Moreover, there is a new network of hydrogen
bonds formed in L858Q, including Arg836 (catalytic loop)Glu758 (𝛼C-helix) and Ala859 (activation loop)-Val765 (𝛼Chelix) interactions. The change in the interaction pattern is
determined by appreciable structural changes, where the 𝛼Chelix and the activation loop come closer to each other (𝛼Chelix moves down, the activation loop moves up, and the Ploop moves away from the 𝛼C-helix). Structural modeling of
the L858R and L861Q mutations in EGFR points to a similar
intrinsic mechanism of activation, which may imply a severe
destabilization of the wild-type inactive conformation upon
mutation and shifting equilibrium towards the active-like
state of the enzyme, which would arguably have a detrimental
effect on modulating normal kinase activity.
2.8. Differential Effect of Activating and Inactivating Oncogenic
Mutations on the FGFR Kinases. Constitutive activation of
the FGFR kinase family by a variety of mutations has
been reported in several cancers [64–68]. Among frequent
activating FGFR2 mutations in endometrial carcinomas are
I548V, N550K, E565G, E565A, N549H, N540K, K526E,
K660E, R678G, K641R, and G663E [64]. Three somatic
FGFR2 endometrial mutations in the catalytic domain have
an identical missense change reported in the paralogous
position in FGFR3 (I538V, N540K, and K650E) in a skeletal
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Figure 9: Computational modeling of the EGFR-L858R mutant. (a) The predicted structure of the L858R EGFR mutant. (b) A close-up
of functionally important residues and interactions stabilizing the EGFR mutant. (c) A close-up comparison between conformations of the
activation loop in the wild-type EGFR crystal structure (pdb entry 2J6M, green), L858R mutant crystal structure (pdb entry 2ITT, pink), and
two best predicted mutant structures. The activation loop conformation of the two lowest energy predicted models of EGFR-L858R are shown
in blue and cyan. The first predicted model of the complete EGFR-L858R protein structure has RMSD = 1.98 Å from the crystal structure (with
the activation loop in blue). The second lowest energy model of the complete EGFR-L858R structure is within RMSD = 2.52 Å from the crystal
structure (with the activation loop in cyan).

chondrodysplasia [64]. In lung squamous cell carcinoma,
the FGFR family is also one of the most frequently altered
receptor tyrosine kinase families. The lung cancer activating
mutations in FGFR2 include W290C, E471Q, T787K, and
kinase domain mutations K660E and K660N [65]. The
respective activating mutations in FGFR3 include R248C,
S249C, S435C, and kinase domain mutation K717M [65].
The loss-of-function (LOF) FGFR2 kinase domain mutations
identified in melanoma tumors cell lines include E636K,
M640I, I642V, R759Q, E475K, D530N, A648T, and G701S
[66]. Targeted genetic dependency screen is an efficient
approach to identify somatic cancer alterations and was used
to identify gain-of-function (GOF) mutations in lung cancer
for FGFR4, MAP3K9, and PAK5 kinases [119]. Among discovered mutations were activating FGFR4 mutations P712T,
H713R, S772N, and D127H, as well as a kinase-dead alteration
K503M [119].
Mapping of the FGFR2/FGFR3 cancer mutations onto
the crystal structures and conformational dynamics profiles

demonstrated that mutations are broadly distributed in the
kinase domain occupying different segments (Figure 10).
Despite this diversity, we observed a subtle yet important
distinction between dynamics profiles of the activating and
kinase-dead mutations. The activating FGFR2 mutations
simulated using the unphosphorylated (Figure 10(a)) and
phosphorylated crystal structure (Figure 10(b)) are typically
located either in flexible regions or at the borders between
structurally stable and mobile regions. In contrast, the kinasedead FGFR2 mutations are associated with the structurally
stable and predominantly rigid segments of the kinase
domain (Figures 10(c) and 10(d)). Some of the FGFR2
inactivating mutations target hydrophobic residues M640,
I642, and A648 residues located near the 𝛽8 strand that
precedes the activation loop of the kinase domain. Structural
stability of these residues is determined by their interactions
with the 𝛼E-helix in the innermost core of the C-lobe of the
kinase domain. As a result even modest substitutions of these
residues with the smaller hydrophobic side chains would
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Figure 10: Functional dynamics and structural map of the FGFR2 and FGFR3 cancer mutations. Functional dynamics and conformational
mobility map of the EGFR2 activating mutations (I548V, N550K, E565G, N549H, N540K, K526E, K660E, R678G, K641R, and G663E)
projected onto the unphosphorylated FGFR2 crystal structure, pdb id 2PSQ (a) and phosphorylated active FGFR2 crystal structure, pdb id
2PVF (b). Dynamic maps of the EGFR2 inactivating mutations (E636K, M640I, I642V, R759Q, E475K, D530N, A648T, and G701S) projected
onto the unphosphorylated FGFR2 crystal structure (c) and the phosphorylated active FGFR2 crystal structure (d). Dynamic map of the
FGFR3 activating mutations (I538V, N540K, and K650E) and inactivating mutation (K508) projected onto the crystal structure of FGFR3
(pdb id 4k33) (e). A surface-based protein representation is employed, colored (blue-to-red) according to the protein residue motilities (from
more rigid-blue regions to more flexible-red regions).

disturb the integrity of the catalytic core of the kinase and lead
to severe alterations in the kinase function and loss of activity.
On the other hand, the relatively high mobility of kinase
residues whose alterations lead to activating mutations can be
explained by their proximity to the borders of high and low
stability regions and hinge sites. Indeed, the internal mobility
of these sites coupled with their prime location critical for
coordinating global motions of the kinase domain could
facilitate conformational transitions between inactive and
active conformations. Our results suggest that the observed
structural and dynamic signatures of activating mutation sites
could reduce a steric barrier for the movement of the kinase
N-lobe toward the C-lobe, which takes place when the kinase
transits from the basal “low” activity state to the “active” state.
2.9. Structural and Dynamic Analysis of Cancer Mutations
in BRAF: Kinase-Inactivating Mutations Stabilize the Inactive
Conformation. The kinase-dead mutant forms of the Asp
residue from the DFG motif have been found in various
kinases where the carboxyl oxygen of this highly conserved

residue plays a critical role in chelating Mg2+ and stabilizing
ATP binding in the catalytic site [60–63]. Mutations of this
Asp to residues that are not negatively charged and thus cannot chelate the Mg2+ causing kinase inactivation. These mutations form a structurally conserved hotspot (Table 1) shared
by many essential kinases including BRAF-D594V [62, 63],
DAPK3-D161N [71], HCK-D378G [60, 61], and LYN-D385Y
[60, 120]. The glycine residue from the DFG motif, which
is adjacent to the Asp residue, is another important mutational hotspot of kinase inactivating mutations and includes
BRAF-G596R, FYN-G410R, EPHA3-G766E, MAPK8-G171S,
CDK11-G175S, and MAST205-G655A [60, 61]. Although
most BRAF mutants display elevated kinase activity compared to the wild type, four cancer-derived mutants have
reduced kinase activity: G466E, G466V, G596R, and D594V.
Among the naturally occurring mutations, two that involve
amino acids of the conserved DFG motif in the activation
loop D594V and G596R are kinase-inactivating alterations.
However, BRAF can promote MEK-ERK activation and
tumor progression through several mechanisms, including
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Figure 11: Functional dynamics and structural map of cancer mutations in the inactive and active BRAF structures. Functional dynamics
and conformational mobility maps of the kinase-dead mutation D594V in the inactive BRAF crystal structure, pdb id 1uwh (a) and activating
V600E mutation in the active BRAF crystal structure of BRAF kinase domain, pdb id 3c4c (b). Structural distribution of the protein kinase
mobility was obtained from MD simulations and is averaged over the two lowest frequency modes. The hydrophobic spine residues (F516L505-I513-L567-H574-I572-V504) are shown in spheres. The D594V residue (a) and D594 residue (b) are shown in sticks and pointed by
arrow. The F595 residue from the DFG motif is shown in spheres and annotated. The position of the BRAF selective inhibitor sorafenib (in
sticks, atom-based coloring) is shown in (a). The hydrophobic spine is partially disassembled in the inactive form (a) as F595 is flipped in
DFG-out position. The spine is fully assembled in the active conformation (b).

the proposed mechanism of tumorigenesis mediated by
kinase-dead BRAF that could cooperate with oncogenic RAS
to induce CRAF activation and MEK-ERK signaling [63].
Most recently, Taylor and coworkers have put forward a
mechanism of allosteric activation of functionally asymmetric RAF dimers [121] where the assembly of the catalytic
and the regulatory spines provides a unifying explanation
for protein kinase activation [82, 83]. Remarkably, a single mutation in the regulatory spine could assemble the
active conformations bypassing the entire regulatory pathway
involving cooperation with RAS, dimerization step, various
phosphorylation events, and allosteric binding to regulatory
partners [121].
We analyzed the structural and dynamic effects of the
D594V mutation on the crystal structures of BRAF kinases
in the context of a possible interplay between the site
of mutation and regulatory spine. In accordance with the
initial experimental conjecture [63] we suggested that the
kinase-inactivating D594V mutation could mimic selective
BRAF inhibitors by stabilizing the catalytically inactive BRAF
conformation. This may cause the interference with the
assembly of the regulatory spine and thus block the formation
of the active conformation. The kinase-inactivating BRAFD594V and activating BRAF-V600E were constructed using
the crystal structures of BRAF in the inactive (pdb id 1uwh,
1uwj) [24] and active states (pdb id 3c4c) [121]. In each
case, we also analyzed the dynamics preferences and stability
of the hydrophobic spine residues (Figure 11). Functional

dynamics analysis and structural maps of conformational
mobility demonstrated that the kinase-dead D594V mutation
may stabilize the inactive state of BRAF (Figure 11(a)). D594
which has a negatively charged polar side chain is thus
replaced with Val that has a nonpolar side chain. As a result
of this mutation, the hydrophobic side chain of the D594V
residue interacts with the hydrophobic spine and together
with F595 could restrict the flexibility of the activation loop
and partly mimic the structural effect of sorafenib which
is high affinity selective inhibitor stabilizing the inactive
conformation of BRAF (Figure 11(a)). This substitution may
induce stabilization of the F595 conformation which could
block the ATP binding site in a similar way as sorafenib.
In agreement with earlier studies [122–124], we found that
D594V cooperates with F595 to stabilize the activation loop
in the catalytically unproductive conformation, thus resulting
in the autoinhibitory mechanism. One could also observe
that this region in the inactive conformation is formed by
structurally stable residues. This suggests that kinase-dead
mutations may occur in the regions of higher structural
stability and in the case of BRAF D594V hydrophobic
modification could increase thermodynamic stability of the
inactive kinase form. As a result, this effect may also increase
steric barrier for conformational transitions to the active
conformation, thus rendering D594V as a kinase-inactivating
mutation. Concurring with our previous findings, we also
observed that the activating BRAF-V600E mutation corresponds to a fairly flexible region of the catalytic domain,
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Figure 12: Functional dynamics and structural map of inactivating cancer mutants in different kinase genes. Functional dynamics and
conformational mobility maps of the kinase mutants were computed using MD simulations of the crystal structures. (a) The dynamic profile
of the MAP2K4 kinase (pdb id 3alo) with the mapped activating mutations (Q142L, R134Q) and inactivating mutations (P326L, S251N, and
N234I). (b) The dynamics profile of EPHA3 (pdb id 2qoq) with the mapped inactivating mutations (R728L, K761N, D6778E, G766E, and
D806N). (c) The dynamics profile of the DAPK3 kinase (pdb id 3bhy) with the mapped inactivating mutations T112M, D161N, and P216S.
(d) The dynamics profile of the TRKB kinase (pdb id 4asz) with the mapped inactivating mutations T695I and D751N. A surface-based
protein representation is employed, colored (blue-to-red) according to the protein residue motilities (from more rigid-blue regions to more
flexible-red regions).

making this site prone to conformational changes that could
facilitate transitions to the active form of BRAF (Figure 11(b)).
2.10. Structural and Dynamic Effects of Kinase-Inactivating
Mutations: Convergent Functional Solutions by Targeting
Structurally Stable Residues. To provide a substantiated comparative analysis of kinase-inactivating mutations, we compared the effect of these mutations on conformational mobility in different kinases including MAP2K4 [69], EPHA3 [70],
DAPK3 [71], and TRKB [72]. In case of MAP2K4 kinase, the
results of activation of Q142L and R134Q were similar to those
seen with the wild type, whereas the most inactive mutants
R154W, P326L, S251N, and N234I produced markedly attenuated kinase activity [69] (Figure 12(a)). Consistent with
previous observations, we found that kinase-inactivating
mutations in MAP2K4 may assemble in structurally stable
regions, while activating mutations or mutants with similar
activation as in the wild-type kinase target more flexible
regions (Figure 12(a)).
EPHA3 mutations are implicated in lung cancer and are
distributed throughout the domains of EPHA3 (Figure 12(b))
[70]. We mapped kinase-inactivating mutations R728L,
K761N, D678E, G766E, and D806N onto conformational
dynamics profile of EPHA3 and monitored their effect on

structural stability of the catalytic core. Similarly, we also
observed that mutational sites which abolish EPHA3 activity correspond to structurally rigid regions, where drastic
alterations may have a devastating effect on kinase function. Moreover, some mutations K761N, G766E, and D806N
are also conserved in tyrosine kinases. Mutations of these
residues may strongly affect structural stability of the catalytic
core and thus kinase function (Figure 12(b)). G766 is located
in an absolutely conserved DFG segment of the activation
loop and is predicted to affect kinase activity. D806 is situated
in the middle of kinase domain and forms two hydrogen
bonds with the neighboring residues. Both G766E and
D806N mutations discovered might be expected to disrupt
the folding of the kinase domain.
DAPK3 is a relatively novel cancer-associated kinase
with functional mutations. Evaluation of nonsynonymous
DAPK3 point mutations in various tumors (T112M, D161N,
and P216S) reveals that all three mutations decrease or abolish
kinase activity [71]. These DAPK3 mutations identified in
cancer patients can significantly suppress the activity of the
kinase. According to our analysis, these mutations have a
combined pattern of rigidity/mobility and cannot be unambiguously assigned to exclusively rigid segments of the catalytic domain. The broad distribution of these mutations and
their position at the C-terminal lobe segments implicated in
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protein binding could indicate that loss of activity in DAPK3
is unlikely associated with the effect on kinase fold but rather
on binding with regulatory partners. TRK kinases include
the three highly homologous proteins TRKA, TRKB, and
TRKC that are strongly associated with central and peripheral
nervous system processes. Recently, colon cancer-derived
mutants, TRKB-T695I and TRKB-D751N, demonstrated a
significantly reduced activity compared to that of wild-type
TRKB. Consistently, upon stimulation these mutants were
impaired in activating TRKB and its downstream effectors
AKT and ERK [72]. In simulations, we used recently revealed
first crystal structures of the TRKB kinase domain in apo
form and complexes with high affinity inhibitors [125]. Our
analysis suggested that structural map of kinase-inactivating
mutations is associated with structurally rigid residues both
inside the catalytic core and belong to the most structurally
stable helices (T695I and D751N), whereas D751N is also
proximal and to the protein-binding region in the C-terminal
lobe (Figure 12(d)). As a result, this may rationalize the fact
that these mutants were essentially irresponsive to activation
stimulus by TRKB ligand BDNF [72].

3. Discussion
The results of our study suggest that that somatic mutations
occurring at structurally conserved positions within the
protein kinase catalytic domain may be statistically enriched
in cancers and form mutational hotspots that promote the
tumorigenic activity of multiple protein kinases. The majority
of activating cancer mutations cause only moderate structural
changes, but may produce considerable local rearrangements
in the conformation of the activation loop. The appreciable structural changes in the activation loop for activating
mutations are exemplified by conformational transitions to
the active-like form of the protein kinase. The discovered
differences in structure and energetics between the wild-type
kinases and cancer mutants point to a common mechanism
of constitutive activation, which may be determined by a
combined effect of the partial destabilization of the inactive
state and a concomitant stabilization of the active-like form
of the enzyme. Since these structures are known natural
protein conformations existing in a dynamic equilibrium,
we suggest that cancer mutations may trigger conformational transitions which mimic the activation process of the
normal kinase. Our results also demonstrated that many
kinase-inactivating mutations across different kinase genes
are often located in structurally rigid sites where mutations
could either stabilize the autoinhibitory inactive state and
prevent activation or severely reduce kinase activity through
detrimental changes in the kinase fold. These findings are
in excellent agreement with the recent analysis of structural
effects of cancer-associated missense mutations in oncogenes
[126]. These studies determined that oncogenic mutations are
less often destabilizing and functional sites are more often
subject to cancer mutations. Interestingly, it was similarly
concluded that mutations located in the protein core are often
destabilizing and may therefore result in loss-of-function.
Our results corroborate with these studies and collectively
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could offer a plausible model for explaining the mechanism of
inactivating mutations in oncogenic proteins beyond protein
kinases. While the structural diversity of wild-type protein
kinases has been illuminated in recent years given the rapidly
increasing body of crystal structures, structural knowledge
of functionally important kinase mutants is limited and
presents an important challenge for “disease-oriented” structural studies of protein families. It is evident that the accuracy
of computational structure predictions for kinase cancer
mutants and the atomic details of activation mechanisms can
be fully understood only when the respective high resolution
crystal structures become available. However, considering
current experimental challenges in dissecting the molecular
basis of cancer causing mutations, the presented evolutionary
and structural analyses of the mutational hotspots in protein
kinases provide useful insights into the mechanistic basis of
activation which agree with available experimental data.
Thus, computational predictions from this study can
inform and facilitate experiments exploring the molecular
pathology of tumorigenesis and implications in rational drug
design of specific cancer therapies. In particular, characterization of the conformational landscape for the wild-type
protein kinases and cancer mutants can provide access to
unique inactive conformations, otherwise hidden in biochemical and structural experiments typically biased towards
the active state of the enzyme. If such alternative states can be
identified and targeted effectively, structural models of cancer
mutants may be employed for identifying new indications,
as well as reengineering and optimizing the clinical effects of
existing drugs. The emerging understanding of evolutionary
and molecular signatures, associated with cancer causing
mutations in protein kinases, may be also useful for design
of personalized agents which target a spectrum of specific
mutational changes occurring in cancer.

4. Materials and Methods
4.1. Sequence Analysis. Disease causing, somatic, and common SNPs were obtained and mapped to kinase sequences
as described in [46, 48]. Disease causing variants represent
a subset of nscSNPs which are found to cause an inherited
disease, while somatic mutations are found in tumors, and
common SNPs are referred to as the ones which have not
been implicated in disease and are somewhat common in the
population. In total, we examined 355 common SNPs, 428
inherited disease causing SNPs, and 541 cancer associated
SNPs. The SNPs were chosen to be composed of a nonredundant set of SNPs, such that no site within a particular
kinase was counted more than once. Known somatic driver
mutations were obtained by searching OMIM [117]. Somatic
and germline mutations from cancer cell lines were obtained
from the kinome resequencing study [60]. The catalogue of
observed somatic mutations was obtained from the cosmic
database [118]. Disease causing and common SNPs were
obtained and mapped to kinase sequences as described in
[49]. A nonredundant set of SNPs was generated so that no
site within a particular kinase was counted more than once. In
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total, 428 disease causing SNPs and 330 common SNPs were
compiled for the analyses.
Kinase sequences were aligned to characteristic catalytic
site motifs. Regions are denoted based on the definitions
provided by Hanks and Hunter [1], where a denotes the intervening region between subdomains. Note that subdomain X
is split into two halves, X(i) and X(ii). The expected probability (𝐸(𝑝)) of an SNP occurring in a region was calculated
separately for common and disease SNPs as follows. The
average length of each region was calculated as the weighted
average of the region length in each kinase considered, where
weights correspond to the total number of SNPs occurring
within each kinase. This weighting helps avoid biases that
might arise as a result of some kinases simply harboring
more SNPs than others. The probability of an SNP occurring
within a particular region purely by chance was computed
as its weighted average length over the sum of every region’s
weighted average length. The probability (𝑃 value) of the
observed total number (𝑥) of SNPs occurring within each
region, where 𝑛 is the total number of SNPs considered, was
calculated using the general binomial distribution as follows:
If 𝑥/𝑛 < 𝐸(𝑝):
𝑥

𝑛
𝑥
𝑛−𝑥
𝑃 value (𝑥) = ( ∑ ( ) ⋅ 𝐸(𝑝) (1 − 𝐸 (𝑝)) ) ⋅ 2.
𝑥
𝑥=0

(1)

If 𝑥/𝑛 > 𝐸(𝑝):
𝑛

𝑛
𝑥
𝑛−𝑥
𝑃 value (𝑥) = ( ∑ ( ) ⋅ 𝐸(𝑝) (1 − 𝐸(𝑝)) ) ⋅ 2.
𝑥
𝑥=𝑥

(2)

Comparisons of the average length per region in the
common and disease SNPs sets, as well as the comparison of
the number of SNPs per region, and the number occurring
within subdomains versus intervening regions were calculated using the normal distribution approximation to the
binomial distribution. Multiple alignments were generated
by using a motif model. Sites with multiple disease SNPs
were considered for further structural analysis. To estimate
whether disease SNPs are position-specific or distributed
randomly throughout the catalytic domain, in addition to a
pairwise correlation, we ran 10,000 Monte Carlo simulations
involving random assignment of disease SNPs. The SNP
distribution resulting from this simulation study compared
to the observed distribution was that zero SNPs occurred at
an average of 19.52 ± 0.03 positions in the simulation versus
46 observed positions; 1 SNP at 67.58 ± 0.06 positions versus
65 observed positions; 2 SNPs at 76.95 ± 0.07 positions versus
47 observed positions; 3 SNPs at 35.04 ± 0.04 positions versus
18 observed positions, 4 SNPs at 7.20 ± 0.03 positions versus
21 observed positions, 5 SNPs at 0.69 ± 0.01 positions versus 3
observed positions, 6 SNPs at 0.03 ± 0.002 positions versus 3
observed positions, 7 SNPs at 0.0002±0.0001 positions versus
3 observed positions, and 8 SNPs at 0.0 ± 0.0 positions versus
1 observed position. The average length of each subdomain
was calculated as the weighted average of the region length
in each kinase considered, where weights correspond to the

total number of SNPs occurring within each kinase. The
probability of an SNP occurring within a particular region
purely by chance was computed as its weighted average
length is divided by the sum of every region’s weighted
average length. The probability (𝑃 value) of the observed
total number of SNPs occurring within each region was then
calculated using the general binomial distribution. Cancer
mutant predictions and analysis were performed as described
in [47]. Briefly, a support vector machine (SVM) was trained
upon common SNPs (presumed neutral) and congenital
disease causing SNPs characterized by a variety of sequence,
structural, and phylogenetic parameters [47]. The threshold
taken for calling an SNP a driver is 0.49 for catalytic domain
mutations and 0.53 for all other mutations as described in
[47].
4.2. Structural Predictions of Kinase Cancer Mutants. Structure predictions of kinase cancer mutants were done using
MODELLER [127] with optimization of side chains by the
SCRWL3 program [128]. The models were then refined using
5000 steps of minimization and 2 ns MD simulations with
the NAMD 2.6 software package [129]. Initial models were
built in MODELLER with a flexible sphere of 5 (Angstrom,
“Å”) around mutated residue. In the final protocol, we
gradually increased the radius of this sphere in 5 Å steps until
the radius reached the 25 Å values (i.e., all residues falling
within this range were treated as flexible). A hybrid protocol
involving a conjugate gradient (CG) minimization, followed
by MD simulations with simulated annealing refinement, was
repeated 20 times to generate 100 initial models for each
cancer mutant in this study. In the optimization stage, we
initially used a conjugate gradient (CG) minimization to
remove unfavorable contacts and to optimize geometry. MD
simulations were then run at increasing temperature values
from 150 K to 1500 K, followed by simulated annealing and
sampling at temperatures of 1500 K, 1000 K, 800 K, 600 K,
500 K, 400 K, 320 K, and 300 K, respectively. The models
were generated using 20 iterations of the MD/SA procedure
and the predicted structural model was chosen out of the
100 models as scored by the MODELLER default scoring
function.
4.3. MD Simulations. 5 ns MD equilibrium simulations were
carried out on the crystal structures and refined structural
models of cancer mutants using NAMD 2.6 [129] with the
CHARMM27 force field [130, 131] and the explicit TIP3P
water model as implemented in NAMD 2.6 [132]. The
VMD program was used for the preparation and analysis
of simulations [133, 134]. The employed MD protocol was
described in full details in our earlier studies [135–137].
In brief, structures were solvated in a water box with the
buffering distance of 10 Å. The system was subjected to
initial minimization for 20,000 steps (40 ps) keeping protein
backbone fixed which was followed by 20,000 steps (40 ps)
of minimization without any constraints. Equilibration was
done in steps by gradually increasing the system temperature
in steps of 20 K starting from 10 K until 310 K and at each
step 15000 steps (30 ps) equilibration was run keeping a
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restraint of 10 Kcal mol−1 Å on protein alpha carbons (C𝛼 ).
Thereafter the system was equilibrated for 150,000 steps
(300 ps) at 310 K (NVT) and then for further 150,000 steps
(300 ps) at 310 K using Langevin piston (NPT) to achieve
uniform pressure. Finally the restrains were removed and the
system was equilibrated for 500,000 steps (1 ns) to prepare the
system for simulation. An NPT simulation was run on the
equilibrated structure for 20 ns keeping the temp at 310 K and
pressure at 1 bar using Langevin piston coupling algorithm.
Nonbonded van der Waals interactions were treated by using
a switching function at 10 Å and reaching zero at a distance of
12 Å.
4.4. Principal Component Analysis. Protein flexibility was
analyzed by combining the results of MD simulations with the
principal component analysis of conformational ensembles
[138, 139]. The covariance matrix between residues (represented by the C𝛼 atoms) 𝑖 and 𝑗 was calculated for each of the
20 ns MD simulation trajectories: snapshots from trajectories
were taken every 200 ps, overall translation and rotation were
removed, and only C𝛼 was kept for analysis.
To obtain collective motion coordinates that represent
the overall dynamics of each trajectory, PCA was performed,
⃗ ) ⋅ (r𝑗⃗ −
in which the covariance matrix 𝐶𝑖𝑗 = ⟨(r𝑖⃗ − r𝑖,ave
⃗r𝑗,ave )⟩ was diagonalized to yield a set of eigenvectors and
eigenvalues. The correlation matrix represents the correlation
between the motion of atom 𝑖 and of atom 𝑗, obtained from
the normalization of the covariance matrix:
Corr𝑖𝑗 =

⃗ ) ⋅ (r𝑗⃗ − r𝑗,ave
⃗ )⟩
⟨(r𝑖⃗ − r𝑖,ave
2

2

√ ⟨r𝑖⃗ − r𝑖,ave
⃗ ⟩ ⟨r𝑗⃗ − r𝑗,ave
⃗ ⟩

.

(3)

The eigenvectors represent the directions in the multidimensional space that correspond to independent modes of
atomic motion, while the eigenvalues represent their corresponding amplitudes [138, 139]. The principal components of
protein motions are analyzed by projecting MD trajectories
onto directions corresponding to the largest eigenvectors.
The correlation value is the normalized covariance matrix,
ranging from −1 to 1. The calculations were performed
using the CARMA package [140] and PCA NEST web-based
service [141].
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